The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
Open accessThe DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
Purpose of Review: The global rise in obesity and type 2 diabetes mellitus (T2DM) presents significant challenges in musculoskeletal care, contributing to increased perioperative complications, impaired bone health, and compromised muscle function. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for glycemic control in T2DM, have demonstrated substantial benefits in weight reduction and metabolic regulation. The purpose of this review is to understand the musculoskeletal biologic and clinical implications of GLP-1RAs. Recent Findings: Evidence suggests that GLP-1RAs may impact musculoskeletal health through anti-inflammatory effects, bone metabolism modulation, and alterations in muscle composition. GLP-1RAs may promote osteoblastogenesis while dampening osteoclast activity to maintain bone mineral density. The result on fracture risk is unclear. Additionally, while GLP-1RAs cause lean mass loss, GLP-1RAs appear to preserve skeletal muscle, reduce fatty infiltration, and enhance fiber formation and function. Further, GLP-1Rs are present in synovial tissue and cartilage, demonstrating downregulation of inflammatory molecules and chondrocyte apoptotic pathways, though clinical studies show variable effects in the setting of osteoarthritis. Overall, the heterogeneity in findings underscores the need for further research to delineate the long-term musculoskeletal effects of GLP-1RAs. Summary: Understanding the musculoskeletal impact of GLP-1RAs is critical for optimizing their integration into orthopedic practice. This review explores the orthopedic implications of GLP-1RAs, highlighting their biologic mechanisms and clinical effects on obesity-related joint inflammation and arthropathy, bone mineral density and fracture risk, and skeletal muscle preservation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there are concerns that long-term exposure of GLP-1 RAs at supratherapeutic or maximum approved maintenance doses may impair muscle cell differentiation and potentially contribute to the development of sarcopenia, despite their potential to improve muscle metabolism and quality [83, 88].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“physical performance and functional outcomes are generally preserved or improved in most studies, particularly when resistance training is maintained”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [71]
Experimental — accuracy not yet measuredIn the citing paper
“GLP-1RAs promote glucose uptake in the skeletal muscle by increasing microvascular blood flow and tissue perfusion and inhibit muscle catabolism via the AMP-activated protein kinase pathway [39, 77, 83].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Recent high quality randomized controlled trials (RCTs) have highlighted the clinical benefits of GLP-1RAs, namely improved glycemic control, cardiovascular risk reduction, and weight management [73–76].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“Up to 40% of overall weight loss with semaglutide, and up to 25% with tirzepatide, is attributed to lean body mass, which raises concerns that the drug therapy may hold a negative effect upon skeletal muscle mass and function [10, 47].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“Recent high quality randomized controlled trials (RCTs) have highlighted the clinical benefits of GLP-1RAs, namely improved glycemic control, cardiovascular risk reduction, and weight management [73–76].”
ANDERSON, J. J., & FELSON, D. T. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114939 · Cited by 892
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“Though initially developed for T2DM management, large trials such as Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) [9 ] and Semaglutide Treatment Effect in People with Obesity (STEP) [10] have consistently shown substantial decreases in body weight and optimization…”
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“Further, GLP-1RA act on thyroid C-cells, increasing calcitonin levels, thereby promoting osteoprotegin expression and inhibiting receptor activator of nuclear factor-κB ligand (RANKL), effectively reducing osteoclast-mediated bone resorption [34, 39, 40].”
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530 · cited 1×
“Increasing evidence indicates that GLP-1RAs are anti-inflammatory, with a direct effect on macrophage adhesion, and anti-apoptotic effects throughout human tissue [ 66, 67].”
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · cited 4×
“While robust clinical trials have established their efficacy in glycemic control, weight loss, and cardiovascular protection [2, 108], further research is warranted to elucidate their direct effects on musculoskel - etal health and orthopedic pathology.”
InfluentialOnce-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Role of Obesity on the Risk for Total Hip or Knee Arthroplasty
Bourne, R., Mukhi, S., Zhu, N., Keresteci, M., & Marin, M. (2007) · Clinical Orthopaedics & Related Research · doi:10.1097/blo.0b013e3181576035 · Cited by 283
Kilhovd, B. K., Berg, T. J., Birkeland, K. I., Thorsby, P., & Hanssen, K. F. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1543 · Cited by 269
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269
Silveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., Ho, A. M.-H., Nersessian, R. S. F., Lima, F. L. M., Silva, M. V., et al. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111091 · Cited by 259
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report
Klein, S. R., & Hobai, I. A. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02440-3 · Cited by 207
Re: Role of Obesity on the Risk for Total Hip or Knee Arthroplasty
Gursu, S., & Aydin, K. (2008) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-008-0174-y · Cited by 205
Su, B., Sheng, H., Zhang, M., Bu, L., Yang, P., Li, L., Li, F., Sheng, C., Han, Y., Qu, S., et al. (2015) · Endocrine · doi:10.1007/s12020-014-0361-4 · Cited by 203
Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193 · cited 2×
“, [3, 4] as promising therapeutic agents.”
InfluentialA Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties
Picke, A.-K., Campbell, G., Napoli, N., Hofbauer, L. C., & Rauner, M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0456 · Cited by 189
Mabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Turcotte, A.-F., O’Connor, S., Morin, S. N., Gibbs, J. C., Willie, B. M., Jean, S., & Gagnon, C. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252487 · Cited by 166
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-05323-7 · Cited by 160 · cited 3×
“Tao et al. analyzed 596 matched T2DM patients undergoing single or multi-level cervical spine decompression and fusion pathways and response [23, 71].”
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
Zibellini, J., Seimon, R. V., Lee, C. M., Gibson, A. A., Hsu, M. S., Shapses, S. A., Nguyen, T. V., & Sainsbury, A. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2564 · Cited by 157 · cited 1×
“[ 32 ].”
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155 · cited 2×
“Iepsen et al. induced weight loss in obese women prior to initiating low-dose liraglutide (1.2 mg/day) and found that the weight-loss–associated decreases in BMD were abolished with GLP-1RA treatment while weight loss was maintained [3] [33, 42].”
InfluentialThe Effect of Exercise on the Prevention of Osteoporosis and Bone Angiogenesis
Tong, X., Chen, X., Zhang, S., Huang, M., Shen, X., Xu, J., & Zou, J. (2019) · BioMed Research International · doi:10.1155/2019/8171897 · Cited by 149
Nuche‐Berenguer, B., Portal‐Núñez, S., Moreno, P., González, N., Acitores, A., López‐Herradón, A., Esbrit, P., Valverde, I., & Villanueva‐Peñacarrillo, M. L. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22243 · Cited by 146
Pereira, M., Jeyabalan, J., Jørgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., Chavassieux, P., Orriss, I. R., Cleasby, M. E., & Chenu, C. (2015) · Bone · doi:10.1016/j.bone.2015.08.006 · Cited by 137 · cited 4×
“In ovari - ectomized mice (a validated model for osteoporosis), exten-din-4 treatment decreased the expression of sclerostin in osteocytes, a key suppressants of bone formation [34, 38].”
InfluentialKim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137 · cited 1×
“In ovari - ectomized mice (a validated model for osteoporosis), exten-din-4 treatment decreased the expression of sclerostin in osteocytes, a key suppressants of bone formation [34, 38].”
Gudbergsen, H., Overgaard, A., Henriksen, M., Wæhrens, E. E., Bliddal, H., Christensen, R., Nielsen, S. M., Boesen, M., Knop, F. K., Astrup, A., et al. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa328 · Cited by 131
Chen, J., Xie, J.-J., Shi, K.-S., Gu, Y.-T., Wu, C.-C., Xuan, J., Ren, Y., Chen, L., Wu, Y.-S., Zhang, X.-L., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0217-y · Cited by 130 · cited 4×
“Furthermore, liraglutide displays an antioxidant effect, reducing TNF-α-induced reactive oxygen species (ROS) and NADPH-oxidase levels, alleviating stress on mitochondrial and endoplasmic reticulum function, and thus reducing chondrocyte apoptosis [22, 69 ].”
InfluentialZhu, H., Zhou, L., Wang, Q., Cai, Q., Yang, F., Jin, H., Chen, Y., Song, Y., & Zhang, C. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-223845 · Cited by 129
The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
Zhao, C., Liang, J., Yang, Y., Yu, M., & Qu, X. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00098 · Cited by 115
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102624 · Cited by 115
Cheng, L., Hu, Y., Li, Y., Cao, X., Bai, N., Lu, T., Li, G., Li, N., Wang, A., & Mao, X. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3168 · Cited by 111
Ryan, P. M., Seltzer, S., Hayward, N. E., Rodriguez, D. A., Sless, R. T., & Hawkes, C. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.05.009 · Cited by 111
Lu, N., Sun, H., Yu, J., Wang, X., Liu, D., Zhao, L., Sun, L., Zhao, H., Tao, B., & Liu, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132744 · Cited by 108
Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?
Magruder, M. L., Yao, V. J. H., Rodriguez, A. N., Ng, M. K., Sasson, V., & Erez, O. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.05.071 · Cited by 106
On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
Linge, J., Heymsfield, S. B., & Dahlqvist Leinhard, O. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz229 · Cited by 103
Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution!
Jones, P. M., Hobai, I. A., & Murphy, P. M. (2023) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-023-02550-y · Cited by 102
GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway
Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119300 · Cited by 101 · cited 3×
“In murine skeletal muscle, GLP-1R activation increased glycogen storage, increased glucose uptake, and enhanced mitochondrial biogenesis [57, 58].”
Magruder, M. L., Miskiewicz, M. J., Rodriguez, A. N., & Mont, M. A. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.12.023 · Cited by 92
Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s381546 · Cited by 91 · cited 2×
“In murine skeletal muscle, GLP-1R activation increased glycogen storage, increased glucose uptake, and enhanced mitochondrial biogenesis [57, 58].”
Que, Q., Guo, X., Zhan, L., Chen, S., Zhang, Z., Ni, X., Ye, B., & Wan, S. (2019) · Journal of Inflammation · doi:10.1186/s12950-019-0218-y · Cited by 90 · cited 3×
“The activation of GLP-1R has a direct effect on gene expression, downregulating NF-κB phosphorylation and nuclear translocation, thereby reducing the expression of pro-inflammatory cytokines and matrix metalloproteinases (MMPs) [68, 69].”
Morey, V. M., Song, Y. D., Whang, J. S., Kang, Y. G., & Kim, T. K. (2015) · The Journal of Arthroplasty · doi:10.1016/j.arth.2015.12.004 · Cited by 87
Houzelle, A., Jörgensen, J. A., Schaart, G., Daemen, S., van Polanen, N., Fealy, C. E., Hesselink, M. K. C., Schrauwen, P., & Hoeks, J. (2021) · Diabetologia · doi:10.1007/s00125-020-05335-w · Cited by 83
Tinsley, G. M., & Heymsfield, S. B. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae164 · Cited by 81 · cited 1×
“Readers should be aware of flawed interpretation of data as lean or fat-free mass is not synonymous with skeletal muscle mass [65].”
Pandey, A., Patel, K. V., Segar, M. W., Ayers, C., Linge, J., Leinhard, O. D., Anker, S. D., Butler, J., Verma, S., Joshi, P. H., et al. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13445 · Cited by 80
Driessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79 · cited 1×
“Similarly, Driessen et al. found no significant change in fracture risk with GLP-1RA use in a retrospective database study [78].”
Association of Physical Activity and Fracture Risk Among Postmenopausal Women
LaMonte, M. J., Wactawski-Wende, J., Larson, J. C., Mai, X., Robbins, J. A., LeBoff, M. S., Chen, Z., Jackson, R. D., LaCroix, A. Z., Ockene, J. K., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.14084 · Cited by 79
Kim, B. I., LaValva, S. M., Parks, M. L., Sculco, P. K., Valle, A. G. D., & Lee, G. (2024) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.00468 · Cited by 76
Tan, Y., Liu, S., & Tang, Q. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02468-5 · Cited by 76
Hulst, A. H., Polderman, J. A. W., Siegelaar, S. E., van Raalte, D. H., DeVries, J. H., Preckel, B., & Hermanides, J. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.10.023 · Cited by 74
Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., et al. (2022) · Nutrients · doi:10.3390/nu14122414 · Cited by 67 · cited 1×
“Notably SMI stabilized after 3 months, with handgrip strength was unchanged after 6 months of treatment [52].”
Terada, T., Johnson, J. A., Norris, C. M., Padwal, R. S., Qiu, W., Sharma, A. M., Janzen, W., & Forhan, M. A. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003282 · Cited by 66
Jing, M., Sun, J., Wu, J., & Zheng, X. (2019) · Europe PMC (PubMed Central) · Cited by 64
Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy
Moellmann, J., Klinkhammer, B. M., Onstein, J., Stöhr, R., Jankowski, V., Jankowski, J., Lebherz, C., Tacke, F., Marx, N., Boor, P., et al. (2018) · Diabetes · doi:10.2337/db17-1212 · Cited by 60
Li, H., Chen, J., Li, B., & Fang, X. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.108968 · Cited by 60
Mbagwu, C., Sloan, M., Neuwirth, A. L., Charette, R. S., Baldwin, K. D., Kamath, A. F., Mason, B. S., & Nelson, C. L. (2020) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-19-00057 · Cited by 58
Du, X., Zhang, H., Zhang, W., Wang, Q., Wang, W., Ge, G., Bai, J., Guo, X., Zhang, Y., Jiang, X., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105732 · Cited by 55
Ejarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53 · cited 1×
“Secreted from intestinal L-cells in response to food ingestion, GLP-1 enhances glucose-dependent insulin secretion while suppressing glucagon release, thereby promoting effective glycemic control [ 14– 16].”
Ozeki, Y., Masaki, T., Kamata, A., Miyamoto, S., Yoshida, Y., Okamoto, M., Gotoh, K., & Shibata, H. (2022) · Medicines · doi:10.3390/medicines9090047 · Cited by 53
AOYAMA, E., WATARI, I., PODYMA-INOUE, K. A., YANAGISHITA, M., & ONO, T. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1787 · Cited by 52
Surgical Site Infection Prevention Bundle in Cardiac Surgery
Andrade, L. S. D., Siliprandi, E. M. O., Karsburg, L. L., Berlesi, F. P., Carvalho, O. L. D. F., da Rosa, D. S., & dos Santos, R. P. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190070 · Cited by 52
Uchiyama, S., Sada, Y., Mihara, S., Sasaki, Y., Sone, M., & Tanaka, Y. (2023) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4987 · Cited by 52
Wiener, J. M., Sanghvi, P. A., Vlastaris, K., Mroz, T. E., Belding, J., Kaelber, D. C., Olson, T. E., Francis, K. P., Adams, J. S., Bernthal, N. M., et al. (2025) · Spine · doi:10.1097/brs.0000000000005283 · Cited by 52
Li, X., Yang, L., & Chen, L. (2024) · International Journal of Endocrinology · doi:10.1155/2024/1785321 · Cited by 50
Lawand, J. J., Tansey, P. J., Ghali, A. N., Tye, C. B., Hantouly, A. T., Fares, M. Y., Khan, A. Z., Somerson, J. S., & Abboud, J. A. (2024) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2024.09.012 · Cited by 45
Qin, J., & Song, L. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01036-0 · Cited by 44
Elsabbagh, Z., Haft, M. A., Murali, S., Best, M. J., McFarland, E. G., & Srikumaran, U. (2024) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2024.07.045 · Cited by 43
Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes
Zheng, W., Pan, H., Wei, L., Gao, F., & Lin, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.034 · Cited by 42
Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide
Chang, R., Zhang, X., Qiao, A., Dai, A., Belousoff, M. J., Tan, Q., Shao, L., Zhong, L., Lin, G., Liang, Y.-L., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013793 · Cited by 39
Use of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 39
Seddio, A. E., Gouzoulis, M. J., Vasudevan, R. S., Dhodapkar, M. M., Jabbouri, S. S., Varthi, A. G., Rubio, D. R., & Grauer, J. N. (2024) · The Spine Journal · doi:10.1016/j.spinee.2024.10.011 · Cited by 38
Porto, J. R., Lavu, M. S., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2025) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671241297157 · Cited by 38
Jeon, Y. K., Bae, M. J., Kim, J. I., Kim, J. H., Choi, S. J., Kwon, S. K., An, J. H., Kim, S. S., Kim, B. H., Kim, Y. K., et al. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.567 · Cited by 35
Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD
Yen, F., Hsu, C., Wei, J. C., Tsai, F., Huang, Y., Yu, T., & Hwu, C. (2024) · Thorax · doi:10.1136/thorax-2023-221040 · Cited by 33
Kakegawa, T., Sugimoto, K., Saito, K., Yunaiyama, D., Araki, Y., Wada, T., Takahashi, H., Yoshimasu, Y., Takeuchi, H., & Itoi, T. (2024) · Medicine · doi:10.1097/md.0000000000038444 · Cited by 32
Association of insulin resistance and GLP-2 secretion in obesity: a pilot study
Geloneze, B., Lima, M. M. D. O., Pareja, J. C., Barreto, M. R. L., & Magro, D. O. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000800008 · Cited by 29
Kim, H., Choi, S., Gu, M., Ko, S., Kwon, J.-H., Han, J., Kim, J. H., & Kim, M. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3843 · Cited by 29
Seddio, A. E., Moran, J. T., Gouzoulis, M. J., Garbis, N. G., Salazar, D. H., Grauer, J. N., & Jimenez, A. E. (2024) · Arthroscopy The Journal of Arthroscopic and Related Surgery · doi:10.1016/j.arthro.2024.09.057 · Cited by 29
Akyay, Ö. Z., Cantürk, Z., Selek, A., Çetinarslan, B., Tarkun, İ., Çakmak, Y., & Baydemır, C. (2023) · Medicine · doi:10.1097/md.0000000000035394 · Cited by 26
Xu, T., Ranganathan, S., Halm‐Lutterodt, N. V., Garcia-Vargas, J., Wu, A., Karnati, J., Shankar, S., Agyeman, N., Ashraf, A., Barve, P., et al. (2024) · Spine · doi:10.1097/brs.0000000000005099 · Cited by 26
Khalid, S. I., Massaad, E., Thomson, K. B., & Shin, J. H. (2024) · Journal of Neurosurgery Spine · doi:10.3171/2024.6.spine24141 · Cited by 25
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22
Sarcopenia‐related changes in serum GLP‐1 level affect myogenic differentiation
Huang, H., Wang, Y., Jiang, H., Yu, H. W., Chen, Y., Chiou, A., & Kuo, J. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13524 · Cited by 22 · cited 1×
“This same study highlights that sarcopenic individuals demonstrate increased GLP-1 [60].”
Abdulmalik, S., Ramos, D. M., Rudraiah, S., Banasavadi‐Siddegowda, Y., & Kumbar, S. G. (2021) · Differentiation · doi:10.1016/j.diff.2021.05.001 · Cited by 21
Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health
Singh, K., Aulakh, S. K., Nijjar, G. S., Singh, S., Sandhu, A. P. S., Luthra, S., Tanvir, F., Kaur, Y., Singla, A., & Kaur, M. S. (2024) · Cureus · doi:10.7759/cureus.64738 · Cited by 20
Sex-related differences in periprosthetic joint infection research
Mauro, D. D., Meschini, C., Balato, G., Ascione, T., Festa, E., Bizzoca, D., Moretti, B., Maccauro, G., & Vitiello, R. (2024) · Journal of Bone and Joint Infection · doi:10.5194/jbji-9-137-2024 · Cited by 19
Fan, Y.-C., Peng, S.-Y., Chang, C., Lee, C., Huang, J., Hsieh, M., & Yang, S. (2023) · Healthcare · doi:10.3390/healthcare11202749 · Cited by 15
Su, Y., Hsieh, P.-C., Lai, E. C., Lin, Y.-C., & Lin, Y.-C. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101545 · Cited by 13
Bergstein, V. E., Ekkel, K., Haft, M. A., Mikula, J. D., Best, M. J., & Srikumaran, U. (2025) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2024.11.041 · Cited by 11
Cox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
Tanday, N., Flatt, P. R., & Irwin, N. (2021) · Diabetic Medicine · doi:10.1111/dme.14699 · Cited by 10
Jiang, N., Su, D., Chen, D., Huang, S., Tang, C., Jing, L., Yang, C.-Y., Zhou, Z., Yan, Z., & Han, J. D. J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01049 · Cited by 10
Regulation of glucose kinetics during exercise by the glucagon‐like peptide‐1 receptor
Burmeister, M. A., Bracy, D. P., James, F. D., Holt, R. M., Ayala, J. E., King, E. M., Wasserman, D. H., Drucker, D. J., & Ayala, J. E. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.234914 · Cited by 6
Morettini, M., Palumbo, M. C., Bottiglione, A., Danieli, A., Giudice, S. D., Burattini, L., & Tura, A. (2024) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2024.108018 · Cited by 5
Elder, M. J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211049032 · Cited by 2
Villareal, D. T. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.22.2502 · Cited by 1 · cited 2×
“In fact, a 10% reduction in body weight has been associated with 2.2% decrease in lumbar and total hip BMD [31].”
Influential
Cited by
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 53
Sawicka‐Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A. A., Lu, P.-Y., & Ruchała, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02088-1 · Cited by 24
Țica, O., Romanul, I. M., Ciavoi, G., Pantea, V. A., Scrobotă, I., Șipoș, L. R., Daina, C. M., & Ţică, O. (2025) · Biomedicines · doi:10.3390/biomedicines13092309 · Cited by 22
Qaisar, R., Khan, I. U., Rehman, A. U., Iqbal, M. S., Ahmad, F., & Karim, A. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70253 · Cited by 20
Šantić, R., Martinovic, L., Pavlović, N., Rušić, D., Kumrić, M., Martinović, D., Kurir, T. T., & Božić, J. (2026) · Metabolites · doi:10.3390/metabo16060364 · Cited by 11
Metadata
- Authors
- Gatto, A., Liu, K., Milan, N., & Wong, S.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Gatto, Andrew
- Venue
- Current Reviews in Musculoskeletal Medicine
- Published
- 2025-05-15
- Volume
- 18
- Issue
- 10
- Pages
- 469-480
- ISSN
- 1935-973X (ISSN-L)
- 1935-9748
- PMC
- PMC12325148
- OpenAlex
- W4410414424
- Cited by
- 55
- References
- 107
- Citations by year
- 2026: 46 · 2025: 9
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Reviews in Musculoskeletal Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Keywords
- GLP-1 receptor agonists, musculoskeletal health, type 2 diabetes, obesity, bone mineral density, osteoblastogenesis, osteoclast activity, fracture risk, lean mass loss, muscle fat infiltration, osteoarthritis, synovium, cartilage, chondrocyte apoptosis, joint inflammation, orthopedic care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.